Controlling Bacterial Amyloid Formation and the Influence of Curli Subunits on Pathogenic Alpha-synuclein Aggregation
控制细菌淀粉样蛋白的形成以及 Curli 亚基对致病性 α-突触核蛋白聚集的影响
基本信息
- 批准号:10369667
- 负责人:
- 金额:$ 30.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAmyloidAmyloid beta-Protein PrecursorAmyloid fibersAntimicrobial ResistanceBacteriaBehavioralBindingBiochemicalBiogenesisBiological AssayBiological ProcessBrainCell surfaceChemicalsCollaborationsDiseaseEnsureEnterobacteriaceaeEscherichia coliExtracellular MatrixFiberFluorescence MicroscopyGenesGeneticGenomeGram-Negative BacteriaGrantHumanHuman MicrobiomeIn VitroKnowledgeLeadLearningLifeLinkMembraneMicrobial BiofilmsMinorModelingMolecular ChaperonesMusNerve DegenerationNeurodegenerative DisordersOutcomeParkinson DiseasePathogenesisPathogenicityPathway interactionsPolymersPropertyProtein SubunitsProteinsSeedsSpecificitySymptomsSystemTherapeuticTimeToxic effectUropathogenic E. coliVariantWorkalpha synucleinamyloid formationassociated symptombiophysical propertiescytotoxicexperimental studyextracellulargut bacteriagut microbiotahost colonizationhuman diseasemicrobialmutantnovel therapeuticsperiplasmpolymerizationpreventprotein foldingprotein misfoldingsynuclein
项目摘要
Escherichia coli (E.coli) and other enteric bacteria are a major cause of human diseases. Biofilm formation
contributes greatly to bacterial persistence and antimicrobial resistance in the host. Many Enterobacteriaceae,
such as E. coli, produce functional amyloid fibers called curli as a major proteinaceous component of their
extracellular matrix. It is now clear that functional amyloids are widespread, with examples found throughout
cellular life. The curli system in E. coli provides a rich and high throughput genetic and biochemical toolbox for
the study of amyloid formation. The work has contributed to a curli assembly model where the main fiber
component CsgA and the minor subunit CsgB are secreted through the outer membrane-located CsgG. CsgB
attaches to the surface of the cell and templates the folding of CsgA into an amyloid fiber. CsgA subunits that
inappropriately polymerize in the periplasm are inhibited from amyloid accumulation via CsgC. The exquisitely-
controlled curli biogenesis system ensures that E. coli is not exposed to the potentially cytotoxic outcomes of
amyloid formation.
Uncontrolled or inappropriate amyloid formation results in several neurodegenerative diseases, including
Parkinson’s. The hallmark of Parkinson’s disease is the amyloid aggregation of alpha-synuclein, although it is
unknown how amyloid formation is initiated. Colonization of mice with curli amyloid producing bacteria results
in alpha-synuclein amyloid formation and Parkinson’s like symptoms. Furthermore, purified CsgA protein can
accelerate alpha-synuclein amyloid formation in vitro. Therefore, it is imperative to learn how E. coli controls
curli amyloid formation and how CsgA can accelerate alpha-synuclein amyloid formation. Interestingly, CsgC
from E. coli can inhibit CsgA and alpha-synuclein amyloid formation. Knowledge gained from the following
experiments will have implications for microbial pathogenesis, general protein folding, and amyloid biogenesis,
thus paving the way for new therapies that rationally target these critical biological processes. In Aim 1 The
mechanism and specificity of CsgC will be revealed, including how CsgC functions to inhibit CsgA and alpha-
synuclein polymerization at low stoichiometric ratios. In Aim 2 The relationship between the intrinsic ability of
CsgA to form amyloid and its ability to accelerate alpha-synuclein amyloid formation will be assessed. Finally,
in Aim 3 CsgA and CsgC-like proteins in the sequenced genomes of the human gut microbiota will be
identified and biochemically characterized. Together the successful completion of these aims will give an
overall understanding of the mechanism of amyloid inhibitory activity and the interactions between bacterial
amyloid formation and neurodegenerative diseases.
大肠杆菌(E.coli)和其他肠道细菌是人类疾病的主要原因。生物膜的形成
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Richard Chapman其他文献
Matthew Richard Chapman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Richard Chapman', 18)}}的其他基金
Controlling Bacterial Amyloid Formation and the Influence of Curli Subunits on Pathogenic Alpha-synuclein Aggregation
控制细菌淀粉样蛋白的形成以及 Curli 亚基对致病性 α-突触核蛋白聚集的影响
- 批准号:
9973388 - 财政年份:2016
- 资助金额:
$ 30.43万 - 项目类别:
Controlling Bacterial Amyloid Formation and the Influence of Curli Subunits on Pathogenic Alpha-synuclein Aggregation
控制细菌淀粉样蛋白的形成以及 Curli 亚基对致病性 α-突触核蛋白聚集的影响
- 批准号:
10586077 - 财政年份:2016
- 资助金额:
$ 30.43万 - 项目类别:
Protein and Chemical Modulation of Curli Amyloid Biogenesis
Curli 淀粉样蛋白生物发生的蛋白质和化学调节
- 批准号:
9078907 - 财政年份:2016
- 资助金额:
$ 30.43万 - 项目类别:
FASEB SRC on Molecular Mechanisms and Physiological Consequences of Protein Aggregation
FASEB SRC 关于蛋白质聚集的分子机制和生理后果
- 批准号:
8910849 - 财政年份:2015
- 资助金额:
$ 30.43万 - 项目类别:
相似国自然基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
- 批准号:
- 批准年份:2020
- 资助金额:63 万元
- 项目类别:面上项目
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
- 批准号:81870666
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
- 批准号:81601123
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
- 批准号:30971012
- 批准年份:2009
- 资助金额:35.0 万元
- 项目类别:面上项目
抗阿兹海默病Beta-Amyloid寡聚物单链可变区抗体的筛选及其动物试验
- 批准号:30570622
- 批准年份:2005
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Amyloid Beta Protein Precursor Influences Cerebral Thrombosis
淀粉样β蛋白前体影响脑血栓形成
- 批准号:
7615075 - 财政年份:2006
- 资助金额:
$ 30.43万 - 项目类别:
Amyloid Beta Protein Precursor Influences Cerebral Thrombosis
淀粉样β蛋白前体影响脑血栓形成
- 批准号:
7416629 - 财政年份:2006
- 资助金额:
$ 30.43万 - 项目类别:
Amyloid Beta Protein Precursor Influences Cerebral Thrombosis
淀粉样β蛋白前体影响脑血栓形成
- 批准号:
7809522 - 财政年份:2006
- 资助金额:
$ 30.43万 - 项目类别:
Amyloid Beta Protein Precursor Influences Cerebral Thrombosis
淀粉样β蛋白前体影响脑血栓形成
- 批准号:
7229435 - 财政年份:2006
- 资助金额:
$ 30.43万 - 项目类别:
ROLES OF VASCULAR AMYLOID BETA PROTEIN PRECURSOR
血管淀粉样蛋白前体的作用
- 批准号:
2668617 - 财政年份:1995
- 资助金额:
$ 30.43万 - 项目类别:
ROLES OF VASCULAR AMYLOID BETA PROTEIN PRECURSOR
血管淀粉样蛋白前体的作用
- 批准号:
2378652 - 财政年份:1995
- 资助金额:
$ 30.43万 - 项目类别:
ROLES OF VASCULAR AMYLOID BETA PROTEIN PRECURSOR
血管淀粉样蛋白前体的作用
- 批准号:
2211377 - 财政年份:1995
- 资助金额:
$ 30.43万 - 项目类别:
ROLES OF VASCULAR AMYLOID BETA PROTEIN PRECURSOR
血管淀粉样蛋白前体的作用
- 批准号:
2211376 - 财政年份:1995
- 资助金额:
$ 30.43万 - 项目类别:
ROLES OF VASCULAR AMYLOID BETA PROTEIN PRECURSOR
血管淀粉样蛋白前体的作用
- 批准号:
2883193 - 财政年份:1995
- 资助金额:
$ 30.43万 - 项目类别:
Development of iagnostic tool of Arzheimer's discase with use of platelet factor XI and Amyloid beta-protein precursor
使用血小板因子 XI 和淀粉样 β 蛋白前体开发阿茨海默病诊断工具
- 批准号:
05671934 - 财政年份:1993
- 资助金额:
$ 30.43万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)